Trial Profile

A Phase Ib, Single Arm, Open Study of TQB2450 Combined With Anlotinib in Subjects With Relapsed / Refractory Ovarian Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer
Focus Therapeutic Use
Acronyms ACTION
Sponsors Chia Tai Tianqing Pharmaceutical Group

Most Recent Events

08 Jun 2021 Results (n=33) assessing the activity and safety of TQB2450 plus the antiangiogenic multi-target tyrosine kinase inhibitor anlotinib in patients with recurrent advanced ovarian cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology
10 Jan 2021 Planned number of patients changed from 30 to 90.
30 Jun 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com